Yesterday, the EVP, GC & Sec of Tandem Diabetes (TNDM), David B. Berger, bought shares of TNDM for $25.9K.
This recent transaction increases David B. Berger’s holding in the company by 566.57% to a total of $65.81K. This is Berger’s first transaction since reporting a Sell transaction on SNMX back in May 2011
See today’s analyst top recommended stocks >>
Based on Tandem Diabetes’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $46.26 million and GAAP net loss of $34.25 million. In comparison, last year the company earned revenue of $27 million and had a GAAP net loss of $16.04 million. Currently, Tandem Diabetes has an average volume of 1.21M. The Company has a Price to Book ratio of 16.6433.
Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $51.14, reflecting a 52.7% upside. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy TNDM. Six different firms, including Craig-Hallum and Oppenheimer, currently also have a Buy rating on the stock.
The insider sentiment on Tandem Diabetes has been negative according to 21 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
David B. Berger’s trades have generated a 46.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
